trending Market Intelligence /marketintelligence/en/news-insights/trending/ymafn6ieuovumwmxyrwkkq2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Pfizer skin disease drug bags US FDA breakthrough therapy designation

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Pfizer skin disease drug bags US FDA breakthrough therapy designation

Pfizer Inc. received the U.S. Food and Drug Administration's breakthrough therapy designation for PF-04965842 to treat a skin disease.

The drug is being developed as a treatment of moderate to severe atopic dermatitis, a chronic inflammatory disease that makes the skin red and itchy.

The designation will help expedite development and review of the drug which targets the Janus kinase, or JAK, family of enzymes in the body.

The U.S. regulator previously awarded the same designation to AbbVie Inc.'s ABT-494, or upadacitinib, another JAK inhibitor being investigated as a treatment for moderate to severe atopic dermatitis.